文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

现场笔记:扩大分娩医院参与儿童疫苗计划以增加婴儿呼吸道合胞病毒免疫——美国,2023年10月至2025年3月

Notes from the Field: Expanding Birthing Hospital Enrollment in the Vaccines for Children Program to Increase Infant Immunization Against Respiratory Syncytial Virus - United States, October 2023-March 2025.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2025-11-20

美国将长效单克隆抗体尼塞韦单抗纳入儿童疫苗(VFC)计划后,本文描述了美国分娩医院参与VFC计划的情况。VFC覆盖约52.2%的19-35月龄儿童,其中93.4%由医疗补助保险。参与VFC的分娩医院可向符合条件儿童免费提供尼塞韦单抗。

要点

  • 2023年免疫实践咨询委员会推荐孕妇接种RSV疫苗或婴儿使用尼塞韦单抗预防严重RSV。
  • 尼塞韦单抗推荐用于<8月龄婴儿首个RSV流行季,理想情况在出生住院期间或生后第一周内给药。
  • 2023年9月免疫实践咨询委员会决议将尼塞韦单抗纳入VFC计划,符合条件儿童可免费获得。

核心结论

  • 分娩医院参与VFC计划有可能扩大婴儿针对RSV的免疫覆盖。

研究设计与样本

  • 本文为现场笔记,描述自尼塞韦单抗引入以来美国分娩医院参与VFC计划的情况;分娩医院指上一年有超过一次分娩或至少有一张注册产科床位。

主要发现

  • 美国19-35月龄儿童中约一半(52.2%)符合VFC条件,其中93.4%由医疗补助保险。
  • 医疗补助保险婴儿严重RSV感染发病率高于私人保险婴儿。
  • 参与VFC计划的提供者可向符合条件儿童免费给予尼塞韦单抗。

关键数值与推荐

  • 2023年免疫实践咨询委员会推荐两种预防婴儿严重RSV的方案:孕期孕妇接种RSV疫苗或婴儿使用尼塞韦单抗。
  • 尼塞韦单抗推荐用于<8月龄婴儿首个RSV流行季(美国大部分地区为10月至次年3月),理想情况在出生住院期间或生后第一周内给药。
  • 2023年9月免疫实践咨询委员会通过决议将尼塞韦单抗加入VFC计划,为符合条件儿童免费提供。
  • VFC符合条件的儿童包括无保险或保险不足、通过医疗补助保险投保、或美洲印第安人/阿拉斯加原住民。

临床怎么用

  • 参与VFC计划的提供者可向符合条件儿童免费给予尼塞韦单抗。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Respiratory syncytial virus (RSV), the leading cause of hospitalization among U.S. infants, results in 50,000-80,000 associated hospitalizations and 100-300 deaths among children aged <5 years each year (1). In 2023, the Advisory Committee on Immunization Practices (ACIP) recommended two options for preventing severe RSV in infants: maternal RSV vaccination during pregnancy (2) or administration of nirsevimab, a long-acting monoclonal antibody to infants (1). Nirsevimab is recommended for infants aged <8 months during their first RSV season (October-March in most of the United States); ideally, it should be administered during the birth hospitalization or within the first week of life. In September 2023, ACIP passed a resolution to add nirsevimab to the Vaccines for Children (VFC) Program, a public-private partnership that provides CDC-purchased vaccines to VFC-eligible children (those who are uninsured or underinsured, insured through Medicaid, or who are American Indian or Alaska Native) at no cost. Approximately one half (52.2%) of U.S. children aged 19-35 months are VFC-eligible, and among those, 93.4% are insured by Medicaid (3). Medicaid-insured infants have a higher incidence of severe RSV infection than do privately insured infants (4). Providers enrolled in the VFC program are able to administer nirsevimab at no cost to eligible children. Enrollment of birthing hospitals in VFC thus has the potential to expand infant immunization against RSV. This report describes enrollment of U.S. birthing hospitals (those with more than one birth during the previous year or at least one registered maternity bed) in the VFC program since the introduction of nirsevimab.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Olmsted KE, Ramsey-Omonua T, Thomas ES, et al. Notes from the Field: Expanding Birthing Hospital Enrollment in the Vaccines for Children Program to Increase Infant Immunization Against Respiratory Syncytial Virus - United States, October 2023-March 2025. MMWR Morb Mortal Wkly Rep. 2025. PMID: 41264520. doi:10.15585/mmwr.mm7437a2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。